Aurobindo Pharma surges on acquiring business and certain assets of Veritaz Healthcare

Aurobindo Pharma is currently trading at Rs. 535.25, up by 6.60 points or 1.25% from its previous closing of Rs. 528.65 on the BSE.

aurobindo pharma gets usfdas nod for guaifenesin extended release tablets
aurobindo pharma gets usfdas nod for guaifenesin extended release tablets

The scrip opened at Rs. 532.95 and has touched a high and low of Rs. 537.00 and Rs. 528.50 respectively. So far 8960 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 1008.75 on 05-Jul-2021 and a 52 week low of Rs. 503.40 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 537.00 and Rs. 506.70 respectively. The current market cap of the company is Rs. 31274.47 crore.

The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 38.30% and 9.86% respectively.

Aurobindo Pharma has completed the acquisition of business and certain assets of Veritaz Healthcare. Earlier, the company had received approval of the Board of Directors of the Company for the acquisition of the same.

Veritaz operates in pharmaceutical industry in India and sells branded generic formulations and other health care related products.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Please share this news

Check Also

LG Electronics hosts grand finale of All India K-Pop Contest 2023

Udaipur : LG Electronics, India’s leading consumer durables brand, hosted the grand finale of the …